Linked Life Data

12517243

Source:http://linkedlifedata.com/resource/pubmed/id/12517243

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
2003-1-8
pubmed:abstractText
The treatment of deep vein thrombosis (DVT) has been evolving over the past 50 years. Initially, unfractionated heparin (UFH) given subcutaneously every 6 h, progressed to constant infusion therapy followed by warfarin, which has become the mainstay of therapy. Over the past 12 years, a new therapy, low molecular weight heparin (LMWH), has proven to be at least as effective or more effective than UFH in the acute treatment of DVT. These drugs are administered subcutaneously, are better absorbed and do not require monitoring. LMWHs have changed the paradigm of caring for patients with DVT. Finally a number of studies with thrombolytic agents have attempted to improve the outcome of DVT by reducing clot burden and preventing the sequelae of thrombotic valvular damage. This paper will review the management of DVT from the acute phase to long-term management.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jan
pubmed:issn
1465-6566
pubmed:author
pubmed:issnType
Print
pubmed:volume
4
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
55-65
pubmed:dateRevised
2005-11-16
pubmed:meshHeading
pubmed:year
2003
pubmed:articleTitle
Current pharmacotherapeutic options for treating deep vein thrombosis.
pubmed:affiliation
Department of Medicine, Jefferson Medical College, Thomas Jefferson University Hospital, PA, USA. Geno.Merli@mail.tju.edu
pubmed:publicationType
Journal Article, Review